2022 Agenda

Carrie Northcott, PhD is a Senior Director/ Project Lead within Digital Medicine and Translational Imaging (DMTI), Early Clinical Development (ECD) at Pfizer. She leads a driven and diverse team that is evaluating and validating the use of wearable digital devices to more fully understand and characterize physiological endpoints, such as quantitatively measuring night-time scratch and sleep. Carrie has a diverse scientific background in Pharmacology, Toxicology, and Physiology which provides unique insight into understanding how these novel digital endpoints provide meaningful information to patients, doctors and researchers to better treat and understand diseases.

Lana is the Managing Director of Hikma Ventures (the corporate VC arm of Hikma Pharmaceuticals PLC) which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations and finance. Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries. Lana co-founded the Innovation & Leadership Advisory Board (ILAB) at Hikma which consists of young Hikma employees whom share a dedication to advancing Hikma and ensuring it is at the frontier of innovation. Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University. She is a board member of Siniora Food Industries PLC and an investment committee member of AB Ventures (the corporate VC arm of Arab Bank PLC).

Pierre Leurent, CEO and co-founder of Voluntis, an Aptar Pharma company, has over 20 years of experience in digital health in the United States and Europe. Prior to starting Voluntis, Pierre worked at GE Medical Systems in its medical imaging software division, and at HealthCenter Internet Services, a vendor of Electronic Medical Record solutions based in Silicon Valley. He is a founding Director of the Digital Therapeutics Alliance, of which he served as Chairman, and a member of Advamed’s Digital Health Executive Leadership Group. Pierre previously co-chaired the digital therapeutics task force of the Personal Connected Health Alliance, a member of HIMSS, and chaired the eHealth France Alliance. He holds a MS from Ecole Centrale Paris.

Mario Moreira is a Principal Consultant with Emergn and has almost two decades worth of experience applying Agile in the enterprise. He focuses on enabling digital transformations for companies within the pharmaceutical industry, and has recently helped clients improve their time to market for drug development. Mario has spoken in numerous conferences and webinars across the globe and has written four Agile books, including The Agile Enterprise.

Abhishek Shah is the Co-founder & CEO of Wellthy Therapeutics. He has more than a decade of healthcare experience and is a thought leader in Digital Therapeutics in Asia. He is an ex-Venture Capitalist and has held leadership positions in a media conglomerate (UTV, now part of Disney) and his healthcare family businesses. He founded Wellthy Therapeutics with the realization of the need for a ‘care continuum’ in the healthcare system that was designed for episodic care.

Executive entrepreneur turned digital health entrepreneur, John’s career includes 17+ years leading global drug development and healthcare innovation. As President of THREAD, I lead our organization to enable our customers to launch, adopt and scale Virtual Visits + eCOA for their decentralized studies.

Named one of the Top 100 Influencers in Digital Health, John provides expertise and execution experience in digital health strategy, remote patient research, virtual clinical trials, Phase I – IV clinical research, patient reported outcomes, patient engagement and mobile health. He is also a regular keynote speaker at global industry events, guest lecturer at Duke University on digital health/innovation and a published author featured in various conferences, journals, articles and media outlets.

Sharon Hanlon is Senior Director, Clinical Trial Engagement & Enrollment at Bristol-Myers Squibb (BMS). Sharon and her team partner with patients, caregivers, patient advocacy groups and clinical trial sites to gather insights which, when applied to clinical trial development and recruitment efforts, create a more patient- and site-friendly experience. Additionally, Sharon and her team are responsible for driving R&D efforts to enhance diverse patient participation in BMS clinical trials, ensuring that our clinical trial populations reflect the patient population of the disease or condition under study.

Sharon has been at BMS for more than 20 years and has held clinical operations positions of increasing responsibility from Line Management to Project Management across multiple therapeutic areas. Sharon is a nurse by training and prior to her time in the pharmaceutical industry, she had a career as a critical care nurse, nurse educator and research nurse coordinator at hospitals in the Philadelphia area. Sharon received her Master of Science in Nursing from Thomas Jefferson University in Philadelphia, PA.

Josh Rose, Vice President, CVS Health Clinical Trial Services (CTS), is a clinical research industry veteran with more than 20 years of experience. He leads the CTS clinical trial delivery business providing patient-first research within designated HealthHUB locations, the home and virtually. Josh is also responsible for CTS strategy and partnerships. Prior to joining CVS Health, Josh was Vice President and Global Head of Strategy for the Research and Development Solutions Business at IQVIA, while also launching and leading its decentralized clinical trial (DCT) and home research nursing service businesses. Josh has an MBA from Duke University and a Bachelor of Science in chemical engineering from the University of Illinois. He lives in Chapel Hill, NC.

Naomi Fried, PhD, is the founder and CEO of PharmStars, the first pharma-focused accelerator for digital health startups. She is also a Managing Partner and co-founder at Ambit Health Ventures, a VC fund focused on early-stage digital health investments.

Previously, Naomi was the CEO of the boutique advisory firm, Health Innovation Strategies, which assisted large healthcare organizations with innovation program design and optimization, digital health strategy, and innovation activities. Naomi was the first VP of Innovation and External Partnerships at Biogen where she developed the firm’s “innovation beyond the molecule strategy.” Prior to that, she was the first Chief Innovation Officer at Boston Children’s Hospital, where she built and led a team to promote digital health and clinical innovation. Prior to that, she was the first VP of Innovation and Advanced Technology at Kaiser Permanente where she led an effort to identify and assess new and emerging health care technology. Naomi is on the board of Wavely Diagnostics and has served on the board of Directors of the American Telemedicine Association and was a member of the Governor of Massachusetts’ Innovation Council.

Naomi received her PhD in Materials Science from MIT and her BS in Chemistry from the University of California, Berkeley.

Charles is a scientist with interests at the intersection of physics, machine learning, and computational biology. Previously, Charles worked as a machine learning engineer at Leap Motion and a computational biologist at Pfizer. He was a Philippe Meyer Fellow in theoretical physics at École Normale Supérieure in Paris, France, and a postdoctoral scientist in biophysics at Boston University.

Charles holds a Ph.D. in biophysics from Harvard University and a B.S. in biophysics from the University of Michigan.

Joel is focused on identifying new investment opportunities in Precision Medicine, Artificial Intelligence, Population Health, Real World Evidence & Health Equity with a focus on Oncology, Vaccines and Infectious Disease.

Joel currently serves on the Boards of Arcadia Healthcare Solutions, CancerIQ and Infectious Disease Connect and is a Board Observer to Verana Health, GNS Healthcare and RxVantage. Joel also manages GHI’s investment in Unite Us and serves as GHI’s representative to Health Tech Capital. Joel volunteers as a guest lecturer in venture capital at Princeton University, serves as a Venture Mentor to NYU’s Stern School of Business and the Cedars-Sinai Digital Health Accelerator and is a frequent panelist and
moderator at industry events including HiMSS and HLTH.

Mr. Krikston has over 25 years of experience in healthcare innovation. Prior to joining Merck GHI in 2013, he was an Investor at Johnson & Johnson Development Corporation where he served on the Boards of GetWell Network and Imacor. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro.

Joel has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University. Mr. Krikston was recognized as a “Rising Star” by Global Corporate Venturing in 2017.

Since joining Lilly in 1999, Jim Parshall has held various technical and leadership positions in manufacturing, IT, and product development. In each of his roles, he has championed disruptive innovation to create significant business impact within the 146-year-old pharmaceutical company. Assuming his current role in 2019, Jim is responsible for identifying, evaluating, and executing external digital health opportunities to support Lilly’s key therapeutic areas.

Prior to his external innovation role, Jim was Lilly’s Director of Software Device Solutions, where he recruited and led a talented and energized team that was passionate about leveraging digital health to improve patient outcomes. This team delivered Lilly’s first Class I app to market in less than one year after project start and received FDA clearance on the company’s first Class II app. Jim has enjoyed serving on boards for small businesses and industry associations. His book, Applying S88: Batch Control from a User’s Perspective, a guide on implementing modular software for manufacturing, continues to influence projects, operations, and thinking worldwide.

Jim earned a B.S. in electrical engineering from Kettering University and an M.S. in electrical engineering from Purdue University. Before joining Lilly, Jim worked as a lead process and automation engineer at Ben & Jerry’s Homemade, where he learned that eating one’s own mistakes could actually taste good.

Frank Vinluan is senior biopharma reporter for MedCity News. Prior to this he was a senior editor at Xconomy where he wrote and edited stories about a wide range of topics including cancer immunotherapy, cell and gene therapies, gene editing technologies, and rare disease drugs. Before moving into biotech journalism, Frank held business reporting positions at The Des Moines Register and The Seattle Times. He wrote his first clinical trials story as a staff reporter at the Triangle Business Journal.

Nathan is the Founder and General Partner of Air Street Capital, a venture capital firm investing in early-stage AI-first technology and life science companies. His investments include Allcyte (acq. Exscientia), Intenseye, Tractable, Graphcore, V7, Mapillary (acq. Facebook), and Thought Machine. Nathan is the co-author of the annual State of AI Report and the newsletter, your guide to AI. Nathan also leads Spinout.fyi, which seeks to improve university spinout creation starting with open data on deal terms, and The RAAIS Foundation, a non-profit that runs the annual RAAIS summit and funds open source AI fellowships.

Nathan holds a Ph.D. in cancer biology from the University of Cambridge and a BA from Williams College.

Chris Gibson, PhD, is the Co-Founder and CEO of Recursion (NASDAQ:RXRX), a clinical-stage pharmatech company leveraging the latest in automation and artificial intelligence to map and navigate biology and chemistry to discover and develop new medicines at scale. Chris developed the technology and approach that seeded Recursion as part of his MD/PhD work in the lab of Co-Founder Dr. Dean Li (currently President of Merck Research Labs) while at the University of Utah. After completing his Ph.D., Chris left medical school to build Recursion into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and management. Chris ‍serves on the Board of BioUtah and is the Chair of BioHive, the public-private partnership driving expansion of Utah’s life-science ecosystem, the fastest growing in the nation. Chris is also active as an advisor and mentor, both formally and informally, of many young biotech founders. Chris enjoys cycling on both the road and the trails that cut through Utah’s great wilderness, as well as spending time with family.

Najat Khan, PhD, is the Chief Data Science Officer and the Global Head of Strategy & Operations for Janssen Research & Development. In these roles Dr Khan leads a team of 100+ data scientists and data engineers to drive deep impact across Janssen’s pipeline and portfolio and shapes Janssen’s R&D strategy, spanning key pipeline and portfolio decisions to new strategic initiatives to deliver on transformational medicines for patients. Dr Khan co-chairs the Johnson & Johnson Data Science Council and is a member of Janssen’s Development and Investment Committees. Dr Khan was a Senior Principal at The Boston Consulting Group and received her Ph.D. in Organic Chemistry from the University of Pennsylvania and her B.A. in Chemistry with a minor in Economics from Colgate University.

Jessica is a Partner at Boston Millennia, investing in high-impact, tech-enabled companies transforming life science research and healthcare globally. Previously, Federer was the Chief Digital Officer at Bayer A.G., leading the global digital transformation for the life sciences leader across consumer health, pharmaceuticals, animal health, and agriculture. There she was recognized as one of the top 100 global CDOs and a leading Health Tech Influencer, adept at translating digital developments into meaningful advancements for both business and society. Federer served on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). Federer began her public health career as an analyst at the Agency for Healthcare Research and Quality in the US Department of Health and Human Services. Federer earned a Bachelor of Science from the George Washington University, and a Master of Public Health from Yale.

Joel is focused on identifying new investment opportunities in Precision Medicine, Artificial Intelligence, Population Health, Real World Evidence & Health Equity with a focus on Oncology, Vaccines and Infectious Disease.

Joel currently serves on the Boards of Arcadia Healthcare Solutions, CancerIQ and Infectious Disease Connect and is a Board Observer to Verana Health, GNS Healthcare and RxVantage. Joel also manages GHI’s investment in Unite Us and serves as GHI’s representative to Health Tech Capital. Joel volunteers as a guest lecturer in venture capital at Princeton University, serves as a Venture Mentor to NYU’s Stern School of Business and the Cedars-Sinai Digital Health Accelerator and is a frequent panelist and
moderator at industry events including HiMSS and HLTH.

Mr. Krikston has over 25 years of experience in healthcare innovation. Prior to joining Merck GHI in 2013, he was an Investor at Johnson & Johnson Development Corporation where he served on the Boards of GetWell Network and Imacor. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro.

Joel has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University. Mr. Krikston was recognized as a “Rising Star” by Global Corporate Venturing in 2017.

Maxim Owen is a Venture Partner at Wavemaker Three-Sixty Health, the leading U.S. early-stage venture capital fund focused 100% on healthcare. Maxim previously led the Ventures team at StartUp Health, the world’s largest early-stage digital health portfolio. Prior to that, he built and led the venture investment team of a prominent New York family office investing across impact-focused sectors. Maxim began his career as a global macro investor at Schroders Investment Management in London, helping manage a $30B portfolio of publicly traded securities.